Fewer than one in 10 individuals eligible to benefit from obesity jabs like Wegovy are able to get them, warns the WHO as it releases its first recommendations on the therapies.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for increased and just access to GLP-1 medication.
Per projections, more than two billion could be obese by 2030 without intervention.
"Our latest guidance recognises that obesity is a chronic disease that can be managed with holistic and ongoing treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are key obstacles to broad availability to the treatments that can aid individuals in losing significant weight, says the organization.
GLP-1 Therapy Supply Crisis
Despite the present best projected scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of those who need them, per the health organization.
The guideline encourages countries and companies to widen availability, via measures such as voluntary licensing.
A patent on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Obesity Jabs Work
The injections imitate a natural hormone to reduce digestion speed, reduce hunger and boost satiety so people reduce food intake.
Patients typically see weight reduction within a few weeks of commencing the weekly injections.
Research indicates people may regain a significant portion after a year of stopping the medication, as their usual hunger resume.
To be above a healthy weight elevates your chance for developing health problems, such as type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight concerns individuals in all nations and was responsible for millions of deaths worldwide in 2024, according to the health agency.
